Paul M. Ayton

3.3k total citations
17 papers, 2.6k citations indexed

About

Paul M. Ayton is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Paul M. Ayton has authored 17 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Hematology and 3 papers in Oncology. Recurrent topics in Paul M. Ayton's work include Acute Myeloid Leukemia Research (13 papers), Protein Degradation and Inhibitors (8 papers) and Genomics and Chromatin Dynamics (6 papers). Paul M. Ayton is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Protein Degradation and Inhibitors (8 papers) and Genomics and Chromatin Dynamics (6 papers). Paul M. Ayton collaborates with scholars based in United States, United Kingdom and India. Paul M. Ayton's co-authors include Michael L. Cleary, Antonio Cozzio, Irving L. Weissman, Emmanuelle Passegué, Holger Karsunky, Bryan D. Young, Tracy Chaplin, Vaskar Saha, Ian D. Hickson and Adrian L. Harris and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Genes & Development.

In The Last Decade

Paul M. Ayton

17 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul M. Ayton United States	15	2.1k	1.2k	483	259	184	17	2.6k
Chi Wai Eric So United Kingdom	29	2.5k 1.2×	1.2k 1.0×	424 0.9×	275 1.1×	197 1.1×	65	3.0k
Robert K. Slany Germany	33	3.1k 1.5×	1.5k 1.3×	304 0.6×	300 1.2×	246 1.3×	68	3.6k
Silvia Grisendi United States	8	1.7k 0.8×	597 0.5×	358 0.7×	104 0.4×	175 1.0×	12	2.1k
Joachim Schwäble Germany	22	1.2k 0.6×	1.1k 0.9×	487 1.0×	113 0.4×	417 2.3×	33	2.1k
Kathrin M. Bernt United States	23	1.8k 0.9×	683 0.6×	453 0.9×	332 1.3×	104 0.6×	58	2.4k
Donatella Venturelli Italy	23	1.1k 0.5×	638 0.5×	307 0.6×	107 0.4×	418 2.3×	58	1.8k
Meredith J. Taylor United States	6	1.8k 0.9×	775 0.6×	270 0.6×	62 0.2×	75 0.4×	11	2.0k
Adam S. Sperling United States	22	1.3k 0.6×	724 0.6×	698 1.4×	58 0.2×	214 1.2×	73	2.1k
Christine Tran Quang France	12	620 0.3×	403 0.3×	507 1.0×	175 0.7×	269 1.5×	21	1.3k
Camille Lobry United States	14	1.1k 0.5×	357 0.3×	374 0.8×	96 0.4×	141 0.8×	25	1.8k

Countries citing papers authored by Paul M. Ayton

Since Specialization

Citations

This map shows the geographic impact of Paul M. Ayton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Ayton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Ayton more than expected).

Fields of papers citing papers by Paul M. Ayton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Ayton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Ayton. The network helps show where Paul M. Ayton may publish in the future.

Co-authorship network of co-authors of Paul M. Ayton

This figure shows the co-authorship network connecting the top 25 collaborators of Paul M. Ayton. A scholar is included among the top collaborators of Paul M. Ayton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul M. Ayton. Paul M. Ayton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Cohen, Ouri, Ela Elyada, Lihi Radomir, et al.. (2024). 800 Preclinical in vivo characterization of the anti-tumor activity of a non-blocking PD-1 antibody fused to attenuated IL-2. Regular and Young Investigator Award Abstracts. A905–A905. 1 indexed citations

2.

Liedtke, Michaela, Paul M. Ayton, Tim C. P. Somervaille, Kevin S. Smith, & Michael L. Cleary. (2010). Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. Blood. 116(1). 63–70. 32 indexed citations

3.

Ayton, Paul M., et al.. (2004). Binding to Nonmethylated CpG DNA Is Essential for Target Recognition, Transactivation, and Myeloid Transformation by an MLL Oncoprotein. Molecular and Cellular Biology. 24(23). 10470–10478. 128 indexed citations

4.

Cozzio, Antonio, Emmanuelle Passegué, Paul M. Ayton, et al.. (2003). Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes & Development. 17(24). 3029–3035. 479 indexed citations

5.

Ayton, Paul M. & Michael L. Cleary. (2003). Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes & Development. 17(18). 2298–2307. 341 indexed citations

6.

Deguchi, Kenji, Paul M. Ayton, Melina Carapeti, et al.. (2003). MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell. 3(3). 259–271. 171 indexed citations

7.

So, Chi Wai Eric, et al.. (2003). Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell. 4(2). 99–110. 146 indexed citations

8.

DiMartino, Jorge, et al.. (2002). The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood. 99(10). 3780–3785. 108 indexed citations

9.

Yokoyama, Akihiko, Issay Kitabayashi, Paul M. Ayton, Michael L. Cleary, & Misao Ohki. (2002). Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood. 100(10). 3710–3718. 123 indexed citations

10.

Ayton, Paul M. & Michael L. Cleary. (2001). Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 20(40). 5695–5707. 390 indexed citations

11.

Ayton, Paul M., Sharon Sneddon, Donald B. Palmer, et al.. (2001). Truncation of the MLL gene in exon 5 by gene targeting leads to early preimplantation lethality of homozygous embryos. genesis. 30(4). 201–212. 64 indexed citations

12.

DiMartino, Jorge, T. R. Miller, Paul M. Ayton, et al.. (2000). A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 96(12). 3887–3893. 86 indexed citations

13.

DiMartino, Jorge, T. R. Miller, Paul M. Ayton, et al.. (2000). A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 96(12). 3887–3893. 8 indexed citations

14.

Hochhauser, Daniel, Paul M. Ayton, R Whitehouse, et al.. (1996). Differential expression of the topoisomerase IIα and β genes in human breast cancers. British Journal of Cancer. 73(12). 1518–1524. 60 indexed citations

15.

Chaplin, Tracy, Paul M. Ayton, Olivier Bernard, et al.. (1995). A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. Blood. 85(6). 1435–1441. 145 indexed citations

16.

Saha, Vaskar, et al.. (1995). The leukemia-associated-protein (LAP) domain, a cysteine-rich motif, is present in a wide range of proteins, including MLL, AF10, and MLLT6 proteins.. Proceedings of the National Academy of Sciences. 92(21). 9737–9741. 127 indexed citations

17.

Jenkins, John R., Paul M. Ayton, T. Alwyn Jones, et al.. (1992). Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Research. 20(21). 5587–5592. 206 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact